


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A compound represented by the following formula (I):



wherein R^1 represents hydrogen;

R^2 represents hydrogen, alkyl, amino, halogen, halogenoalkenyl, carboxyl, alkoxy carbonyl, carbamoyl, *N,N*-dialkylcarbamoyl, *N*-hydroxyalkylcarbamoyl, aryl selected from the group consisting of phenyl, naphthyl, anthryl, phenanthryl and biphenylyl, which has a substituent, or a saturated or unsaturated 5- to 7-membered heterocyclic group selected from the group consisting of furyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, pyrazolinyl, oxazolyl, isoxazolyl, oxazolinyl, thiazolyl, thiazolinyl, thiadiazolyl, furazanyl, pyranyl, pyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolidinyl, piperazinyl, piperidinyl, oxazinyl, oxadiazinyl, morpholinyl, thiazinyl, thiadiazinyl, thiomorpholinyl, tetrazolyl, triazolyl, triazinyl, azepinyl, diazepinyl and triazepinyl, which may have a substituent, wherein the substituent is one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (A):

Group (A):

halogen, hydroxyl, alkyl, alkoxy, halogenoalkyl, cyano, nitro, hydroxyalkyl, carboxyl, alkoxy carbonyl, carboxyalkoxy, alkoxy carbonylalkoxy, aralkyloxy, *N*-alkylaminoalkylcarbonyl,

N,N-dialkylaminoalkylcarbonyl, carboxylalkyl, alkoxy carbonylalkoxy, morpholinocarbonylalkoxy, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N,N*-dialkylaminosulfonyl, sulfo, alkylsulfonyl, alkylsulfonylalkyl, tetrazolyl, trialkyltin, trialkylsilyl, aminosulfonylalkyl, *N*-alkylaminosulfonylalkyl, *N,N*-dialkylaminosulfonylalkyl, aralkyl, alkylsulfonylamino, *N*-alkylaminosulfonylamino, *N,N*-dialkylaminosulfonylamino, *N*-alkylaminoacylamino, *N,N*-dialkylaminoacylamino,

a group represented by the following formula (II):

$-A^1-Y^1$ (II)

wherein A^1 represents a single bond or linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl; and Y^1 represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent,

wherein the substituent on Y^1 is one substituent or 2 or 3 substituents, which are the same or different, selected from the group consisting of halogen, alkyl, halogenoalkyl, carboxyl, alkoxy carbonyl, aminoalkyl, *N*-alkylamino, *N,N*-dialkylamino, *N*-alkylaminoalkyl, *N,N*-dialkylaminoalkyl, *N*-alkyl-*N*-alkoxycarbonylamino and *N*-alkyl-*N*-alkoxycarbonylaminoalkyl,

a group represented by the following formula (III)

$-A^2-(C=O)-Y^2$ (III)

wherein A^2 represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, or linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the carbonyl in the group; and Y^2 represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent,

wherein the substituent on Y^2 represents one substituent or 2 or 3 substituents, which are the same or different, selected from the group consisting of halogen, alkyl, halogenoalkyl, carboxyl, alkoxy carbonyl, aminoalkyl, *N*-alkylamino, *N,N*-dialkylamino, *N*-alkylaminoalkyl, *N,N*-dialkylaminoalkyl, *N*-alkyl-*N*-alkoxy carbonyl amino and *N*-alkyl-*N*-alkoxy carbonyl aminoalkyl,

a group represented by the following formula (IV)



wherein A^3 represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, linear, branched or cyclic- O -alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the nitrogen atom in the group, or linear, branched or cyclic-($C=O$)-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the nitrogen atom in the group; and R^4 and R^5 each independently represents hydrogen, alkyl, hydroxyalkyl, halogenoalkyl, acyl, alkoxy carbonyl, alkylsulfonyl, *N*-alkylamino sulfonyl, *N,N*-dialkylamino sulfonyl, *N*-alkylaminoalkyl carbonyl, *N,N*-dialkylaminoalkyl carbonyl or alkyldiphenylsilyloxyalkyl, and

a group represented by the following formula (V)



wherein A^4 represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, or linear, branched or cyclic- O -alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the carbonyl in the group; and

R⁶ and R⁷ each independently represents hydrogen, alkyl, hydroxyalkyl, halogenoalkyl, acyl, alkoxy carbonyl, alkylsulfonyl, *N*-alkylaminosulfonyl, *N,N*-dialkylaminosulfonyl, *N*-alkylaminoalkyl carbonyl, *N,N*-dialkylaminoalkyl carbonyl or alkyldiphenylsilyloxyalkyl;

R³ represents hydrogen;

Ar represents phenylene, which may have one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (B):

Group (B):

halogen, hydroxyl group, alkyl, alkoxy, halogenoalkyl, cyano, amino, nitro, alkylamino, hydroxyalkyl, carboxyl, alkoxy carbonyl, carbamoyl, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N,N*-dialkylaminosulfonyl, sulfo, trialkyltin and trialkylsilyl;

X represents a single bond; and

G represents halogen, halogenoalkyl, halogenoalkenyl, halogenoalkynyl, alkoxy, alkoxy carbonyl, *N*-alkylamino, *N,N*-dialkylamino, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, a saturated or unsaturated bicyclic or tricyclic condensed hydrocarbon group which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group selected from the group consisting of furyl, thienyl, pyrazolyl, imidazolyl, pyrazolinyl, oxazolyl, isoxazolyl, oxazolinyl, thiazolyl, thiazolinyl, thiadiazolyl, furazanyl, pyranyl, pyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, piperazinyl, pyrrolidinyl, piperidinyl, oxazinyl, oxadiazinyl, morpholinyl, thiazinyl, thiadiazinyl, thiomorpholinyl, tetrazolyl, triazolyl, triazinyl, azepinyl, diazepinyl and triazepinyl, which may have a substituent, or a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group selected from the group consisting of indolyl, indolinyl, isoindolyl, isoindolinyl, indazolyl, quinolyl, dihydroquinolyl, tetrahydroquinolyl, isoquinolyl, tetrahydroisoquinolyl, 4H-

quinolizinyl, quinazolinyl, dihydroquinazolinyl, tetrahydroquinazolinyl, cinnolinyl, tetrahydrocinnolinyl, indolizinyl, tetrahydroindolizinyl, benzothiazolyl, tetrahydrobenzothiazolyl, benzoxazolyl, benzoisothiazolyl, benzoisooxazolyl, benzoimidazolyl, naphthyridinyl, tetrahydronaphthyridinyl, thienopyridyl, tetrahydrothienopyridyl, thiazolopyridyl, tetrahydrothiazolopyridyl, thiazolopyridazinyl, tetrahydrothiazolopyridazinyl, pyrrolopyridyl, dihydropyrrolopyridyl, tetrahydropyrrolopyridyl, pyrrolopyrimidinyl, dihydropyrrolopyrimidinyl, pyridopyrimidinyl, tetrahydropyridopyrimidinyl, pyranothiazolyl, dihydropyranothiazolyl, furopyridyl, tetrahydrofuropyridyl, oxazolopyridyl, tetrahydrooxazolopyridyl, oxazolopyridazinyl, tetrahydrooxazolopyridazinyl, pyrrolothiazolyl, dihydropyrrolothiazolyl, pyrrolooxazolyl, dihydropyrrolooxazolyl, thienopyrrolyl, thiazolopyrimidinyl, thiazolooxazolyl, imidazothiazolyl, imidooxazolyl, imidazopyrimidinyl, imidazopyridyl, tetrahydroimidazopyridyl, pyrazinopyridazinyl, imidazotriazinyl, oxazolopyridyl, benzoazepinyl, benzoazepinyl, tetrahydrobenzoazepinyl, benzodiazepinyl, benzotriazepinyl, thienoazepinyl, tetrahydrothienoazepinyl, thienodiazepinyl, thienotriazepinyl, thiazoloazepinyl, and tetrahydrothiazoloazepinyl, which may have a substituent, wherein the substituent represents one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (C):

Group (C):

halogen, hydroxyl, alkyl, alkoxy, halogenoalkyl, halogenoalkenyl, halogenoalkoxy, cyano, amino, nitro, *N*-alkylamino, *N,N*-dialkylamino, *N*-alkylaminoalkyl, *N,N*-dialkylaminoalkyl, hydroxyalkyl, carboxyl, carboxyalkyl, alkoxycarbonyl, carbamoyl, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N,N*-dialkylaminosulfonyl, oxo, trialkyltin and trialkylsilyl,

or a salt thereof.

2-5. (canceled).

6. (previously presented): The compound represented by formula (I) according to claim 1 wherein G is halogen, halogenoalkenyl, alkoxy, alkoxy carbonyl, *N,N*-dialkylamino, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, or a saturated or unsaturated 5- to 7-membered heterocyclic group selected from the group consisting of furyl, thieryl, pyrazolyl, imidazolyl, pyrazolinyl, oxazolyl, isoxazolyl, oxazolinyl, thiazolyl, thiazolinyl, thiadiazolyl, furazanyl, pyranyl, pyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, piperazinyl, piperidinyl, oxazinyl, oxadiazinyl, morpholinyl, thiazinyl, thiadiazinyl, thiomorpholinyl, tetrazolyl, triazolyl, triazinyl, azepinyl, diazepinyl and triazepinyl, which may have a substituent, or a salt thereof.

7.-9. (canceled).

10. (previously presented): A pharmaceutical composition which comprises the compound represented by formula (I) according to claim 1, or a salt thereof, and a pharmaceutically acceptable carrier.

11-13. (canceled).

14. (previously presented): An agent for treating Creutzfeldt-Jacob disease or Gerstmann Straussler Scheinker syndrome, which comprises the compound represented by formula (I) according to claim 1, or a salt thereof.

15.-17. (canceled).

18. (canceled): .


19.-23 (canceled).

24. (previously presented): The compound of claim 1 according to formula (I), wherein G represents a saturated or unsaturated 5- to 7- membered heterocyclic group selected from the group consisting of furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyrazinyl and triazinyl, which may have a substituent, wherein the substituent is one substituent or 2 or 3 substituents, which are the same or different, selected from Group (C), or a salt thereof.

25. -26 (canceled):

27. (previously presented): The compound of formula (I) according to claim 1, wherein G represents a fluorine atom, an iodine atom, 2-fluoroethyl, 3-fluoropropyl, methoxy; or oxazolyl, pyridyl, oxadiazolyl, imidazopyridyl, imidazothiazolyl or benzothiazolyl, which may have a substituent, wherein the substituent is one substituent or 2 or 3 substituents, which are the same or different, selected from Group (C), or salt thereof.

28. (withdrawn-currently amended): A method for treating Creutzfeldt-Jacob disease or Gerstmann Straussler Scheinker syndrome, which comprises administering a compound represented by formula (I):



wherein

R¹ represents hydrogen;

R² represents hydrogen, alkyl, amino, halogen, halogenoalkenyl, carboxyl, alkoxy carbonyl, carbamoyl, N,N-dialkylcarbamoyl, N-hydroxyalkylcarbamoyl, aryl selected from the group consisting of phenyl, naphthyl, anthryl, phenanthryl and biphenylyl, which has a

substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group selected from the group consisting of furyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, pyrazolinyl, oxazolyl, isoxazolyl, oxazolinyl, thiazolyl, thiazolinyl, thiadiazolyl, furazanyl, pyranyl, pyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolidinyl, piperazinyl, piperidinyl, oxazinyl, oxadiazinyl, morpholinyl, thiazinyl, thiadiazinyl, thiomorpholinyl, tetrazolyl, triazolyl, triazinyl, azepinyl, diazepinyl and triazepinyl, which may have a substituent, wherein the substituent is one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (A):

Group (A):

halogen, hydroxyl, alkyl, alkoxy, halogenoalkyl, cyano, nitro, hydroxyalkyl, carboxyl, alkoxy carbonyl, carboxyalkoxy, alkoxy carbonylalkoxy, aralkyloxy, *N*-alkylaminoalkylcarbonyl, *N,N*-dialkylaminoalkylcarbonyl, carboxyalkyl, alkoxy carbonylalkoxy, morpholinocarbonylalkoxy, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N,N*-dialkylaminosulfonyl, sulfo, alkylsulfonyl, alkylsulfonylalkyl, tetrazolyl, trialkyltin, trialkylsilyl, aminosulfonylalkyl, *N*-alkylaminosulfonylalkyl, *N,N*-dialkylaminosulfonylalkyl, aralkyl, alkylsulfonylamino, *N*-alkylaminosulfonylamino, *N,N*-dialkylaminosulfonylamino, *N*-alkylaminoacylamino, *N,N*-dialkylaminoacylamino,

a group represented by the following formula (II):

$-A^1-Y^1$ (II)

wherein A^1 represents a single bond or linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl; and Y^1 represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent,

wherein the substituent on Y^1 is one substituent or 2 or 3 substituents, which are the same or different, selected from the group consisting of halogen, alkyl, halogenoalkyl, carboxyl, alkoxy carbonyl, aminoalkyl, N -alkylamino, N,N -dialkylamino, N -alkylaminoalkyl, N,N -dialkylaminoalkyl, N -alkyl- N -alkoxycarbonylamino and N -alkyl- N -alkoxycarbonylaminoalkyl, a group represented by the following formula (III)



wherein A^2 represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, or linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the carbonyl in the group; and Y^2 represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent,

wherein the substituent on Y^2 represents one substituent or 2 or 3 substituents, which are the same or different, selected from the group consisting of halogen, alkyl, halogenoalkyl, carboxyl, alkoxy carbonyl, aminoalkyl, N -alkylamino, N,N -dialkylamino, N -alkylaminoalkyl, N,N -dialkylaminoalkyl, N -alkyl- N -alkoxycarbonylamino and N -alkyl- N -alkoxycarbonylaminoalkyl,

a group represented by the following formula (IV)



wherein A^3 represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the nitrogen atom in the group, or linear, branched or cyclic-($C=O$)-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in

which the alkylene binds to the nitrogen atom in the group; and R⁴ and R⁵ each independently represents hydrogen, alkyl, hydroxyalkyl, halogenoalkyl, acyl, alkoxy carbonyl, alkylsulfonyl, N-alkylaminosulfonyl, N,N-dialkylaminosulfonyl, N-alkylaminoalkyl carbonyl, N,N-dialkylaminoalkyl carbonyl or alkyldiphenylsilyloxyalkyl, and

a group represented by the following formula (V)



wherein A⁴ represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, or linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the carbonyl in the group; and

R⁶ and R⁷ each independently represents hydrogen, alkyl, hydroxyalkyl, halogenoalkyl, acyl, alkoxy carbonyl, alkylsulfonyl, N-alkylaminosulfonyl, N,N-dialkylaminosulfonyl, N-alkylaminoalkyl carbonyl, N,N-dialkylaminoalkyl carbonyl or alkyldiphenylsilyloxyalkyl;

R³ represents hydrogen;

Ar represents phenylene, which may have one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (B):

Group (B):

halogen, hydroxyl group, alkyl, alkoxy, halogenoalkyl, cyano, amino, nitro, alkylamino, hydroxyalkyl, carboxyl, alkoxy carbonyl, carbamoyl, mercapto, alkylthio, aminosulfonyl, N-alkylaminosulfonyl, N,N-dialkylaminosulfonyl, sulfo, trialkyltin and trialkylsilyl;

X represents a single bond; and

G represents halogen, halogenoalkyl, halogenoalkenyl, halogenoalkynyl, alkoxy, alkoxy carbonyl, N-alkylamino, N,N-dialkylamino, a saturated or unsaturated 5- or 6-membered

cyclic hydrocarbon group which may have a substituent, a saturated or unsaturated bicyclic or tricyclic condensed hydrocarbon group which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group selected from the group consisting of furyl, thienyl, pyrazolyl, imidazolyl, pyrazoliny, oxazolyl, isoxazolyl, oxazoliny, thiazolyl, thiazoliny, thiadiazolyl, furazanyl, pyranyl, pyridyl, tetrahydropyridyl, pyrimidiny, pyrazinyl, piperazinyl, pyrrolidiny, piperidiny, oxazinyl, oxadiazinyl, morpholinyl, thiazinyl, thiadiazinyl, thiomorpholinyl, tetrazolyl, triazolyl, triazinyl, azepinyl, diazepinyl and triazepinyl, which may have a substituent, or a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group selected from the group consisting of indolyl, indolinyl, isoindolyl, isoindolinyl, indazolyl, quinolyl, dihydroquinolyl, tetrahydroquinolyl, isoquinolyl, tetrahydroisoquinolyl, 4H-quinolizinyl, quinazolinyl, dihydroquinazolinyl, tetrahydroquinazolinyl, cinnolinyl, tetrahydrocinnolinyl, indolizinyl, tetrahydroindolizinyl, benzothiazolyl, tetrahydrobenzothiazolyl, benzoxazolyl, benzoisothiazolyl, benzoisooxazolyl, benzoimidazolyl, naphthyridinyl, tetrahydronaphthyridinyl, thienopyridyl, tetrahydrothienopyridyl, thiazolopyridyl, tetrahydrothiazolopyridyl, thiazolopyridazinyl, tetrahydrothiazolopyridazinyl, pyrrolopyridyl, dihydropyrrolopyridyl, tetrahydropyrrolopyridyl, pyrrolopyrimidiny, dihydropyrrolopyrimidiny, pyridopyrimidiny, tetrahydropyridopyrimidiny, pyranothiazolyl, dihydropyranothiazolyl, furopyridyl, tetrahydrofuropyridyl, oxazolopyridyl, tetrahydrooxazolopyridazinyl, oxazolopyridazinyl, tetrahydrooxazolopyridazinyl, pyrrolothiazolyl, dihydropyrrolothiazolyl, pyrrolooxazolyl, dihydropyrrolooxazolyl, thienopyrrolyl, thiazolopyrimidiny, thiazolooxazolyl, imidazothiazolyl, imidazooxazolyl, imidazopyrimidiny, imidazopyridyl, tetrahydroimidazopyridyl, pyrazinopyridazinyl, imidazotriazinyl, oxazolopyridyl, benzoazepinyl, benzoazepinyl, tetrahydrobenzoazepinyl, benzodiazepinyl,

benzotriazepinyl, thienoazepinyl, tetrahydrothienoazepinyl, thienodiazepinyl, thienotriazepinyl, thiazoloazepinyl, and tetrahydrothiazoloazepinyl, which may have a substituent, wherein the substituent represents one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (C):

Group (C):

halogen, hydroxyl, alkyl, alkoxy, halogenoalkyl, halogenoalkenyl, halogenoalkoxy, cyano, amino, nitro, *N*-alkylamino, *N,N*-dialkylamino, *N*-alkylaminoalkyl, *N,N*-dialkylaminoalkyl, hydroxyalkyl, carboxyl, carboxyalkyl, alkoxycarbonyl, carbamoyl, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N,N*-dialkylaminosulfonyl, oxo, trialkyltin and trialkylsilyl,

or a salt thereof.

29. (previously presented): The compound of formula (I) according to claim 27, wherein G represents oxazolyl, pyridyl, oxadiazolyl, imidazopyridyl, imidazothiazolyl or benzothiazolyl, which may have a substituent, wherein the substituent is one substituent or 2 or 3 substituents, which are the same or different, selected from Group (C), or a salt thereof.

30. (previously presented): The compound of formula (I) according to claim 1 or a salt thereof, wherein G represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent or a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group which may have a substituent, wherein said heterocyclic group is selected from furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyrazinyl, triazinyl, isoindolinyl, quinolyl, tetrahydroquinolyl, isoquinolyl, tetrahydroisoquinolyl, benzothiazolyl, benzoxazolyl, benzoimidazolyl, thienopyridyl, thiazolopyridyl, tetrahydrothiazolopyridyl, pyrrolopyridyl, pyrrolopyrimidinyl, oxazolopyridyl,

tetrahydrooxazolopyridyl, imidazothiazolyl, imidazooxazolyl, imidazopyrimidinyl, imidazopyridyl, and tetrahydroimidazopyridyl, and wherein the substituent is one or 2 or 3 substituents, which are the same or different, selected from Group (C).

31. (previously presented): The compound of formula (I) according to claim 1 or a salt thereof, wherein G represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent or a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group which may have a substituent, wherein said heterocyclic group is selected from furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyrazinyl, triazinyl, tetrahydroquinolyl, tetrahydrothiazolopyridyl, imidazothiazolyl, imidazooxazolyl, imidazopyrimidinyl, imidiazopyridyl and tetrahydroimidazopyridyl, and wherein the substituent is one or 2 or 3 substituents, which are the same or different, selected from Group (C).

32. (new): The compound of formula (I) according to claim 1, which is
4-pyridinecarboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-pyridinecarboxyaldehyde 4-(pyridin-3-yl)phenylhydrazone,
4-pyridinecarboxyaldehyde 4-(6-methylbenzothiazol-2-yl)phenylhydrazone,
4-(4-methylpiperazin-1-yl)benzaldehyde 4-(6-methylbenzothiazol-2-yl)phenylhydrazone,
4-pyridinecarboxyaldehyde 4-(imidazo[1,2-a]pyridin-2-yl)phenylhydrazone,
4-hydroxy-3-methoxybenzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-[N-(2-hydroxyethyl)-N-methylamino]benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
N,N-dimethyl-4-[4-(oxazol-5-yl)phenylhydrazonomethyl]benzamide,
4-(N-methylaminomethyl)thiazol-2-ylcarboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,
2-dimethylaminomethylthiazole-4-carboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,

2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine)carboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,
2-hydroxy-5-[4-(oxazol-5-yl)phenylhydrazonomethyl]benzoic acid,
4-[*N*-(2-fluoroethyl)-*N*-methylamino]benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-(dimethylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-(4-methylpiperazin-1-yl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-(piperazin-1-yl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-(aminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
2-fluoro-4-pyridinecarboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,
2-(4-methylpiperazin-1-yl)-4-pyridinecarboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-fluorobenzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-aminobenzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-[4-(oxazol-5-yl)phenylhydrazonomethyl]benzenesulfonamide,
2-dimethylamino-*N*-{4-[4-(oxazol-5-yl)phenylhydrazonomethyl]phenyl}acetamide,
4-(*N*-methylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
thiazole-5-carboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-(1-aminoethyl)thiazole-2-carboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,
2-dimethylamino-4-pyridinecarboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,
6-dimethylamino-3-pyridinecarboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-(1-aminoethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-pyridinecarboxyaldehyde 4-(6-bromoimidazo[1,2-a]pyridin-2-yl)phenylhydrazone,
4-pyridinecarboxyaldehyde 4-(6-chloroimidazo[1,2-a]pyridin-2-yl)phenylhydrazone,
4-pyridinecarboxyaldehyde 4-(6-fluoroimidazo[1,2-a]pyridin-2-yl)phenylhydrazone,

4-pyridinecarboxyaldehyde 4-(imidazo[2,1-b]thiazol-6-yl)phenylhydrazone,
4-pyridinecarboxyaldehyde 4-(imidazo[1,2-a]pyrimidin-2-yl)phenylhydrazone,
4-pyridinecarboxyaldehyde 4-[1-(2-chloroethyl)-2-methyl-1H-imidazol-4-yl]phenylhydrazone,
3-iodo-4-(*N*-methylaminomethyl)benzaldehyde 4-(pyridin-3-yl)phenylhydrazone,
4-iodo-3-(*N*-methylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
3-chloro-4-(*N*-methylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
3-fluoro-4-(*N*-methylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone, or
benzimidazole-5-carboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone, or a salt thereof.

33. (new): The compound of formula (I) according to claim 1, which is

4-pyridinecarboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-pyridinecarboxyaldehyde 4-(pyridin-3-yl)phenylhydrazone,
4-(4-methylpiperazin-1-yl)benzaldehyde 4-(6-methylbenzothiazol-2-yl)phenylhydrazone,
4-pyridinecarboxyaldehyde 4-(imidazo[1,2-a]pyridin-2-yl)phenylhydrazone,
4-[*N*-(2-hydroxyethyl)-*N*-methylamino]benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-(dimethylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-(4-methylpiperazin-1-yl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-(piperazin-1-yl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
2-fluoro-4-pyridinecarboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-fluorobenzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-aminobenzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-[4-(oxazol-5-yl)phenylhydrazonemethyl]benzenesulfonamide,
4-(*N*-methylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
4-(1-aminoethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,

4-pyridinecarboxyaldehyde 4-(6-chloroimidazo[1,2-a]pyridin-2-yl)phenylhydrazone,
4-pyridinecarboxyaldehyde 4-(6-fluoroimidazo[1,2-a]pyridin-2-yl)phenylhydrazone,
4-pyridinecarboxyaldehyde 4-(imidazo[2,1-b]thiazol-6-yl)phenylhydrazone,
4-pyridinecarboxyaldehyde 4-[1-(2-chloroethyl)-2-methyl-1H-imidazol-4-yl]phenylhydrazone,
3-iodo-4-(*N*-methylaminomethyl)benzaldehyde 4-(pyridin-3-yl)phenylhydrazone
4-iodo-3-(*N*-methylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone
3-chloro-4-(*N*-methylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone, or
3-fluoro-4-(*N*-methylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone, or a salt
thereof.

34. (new): The compound of formula (I) according to claim 1, which is 4-pyridinecarboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone.

35. (new): The compound of formula (I) according to claim 1, which is 4-pyridinecarboxyaldehyde 4-(6-chloroimidazo[1,2-a]pyridin-2-yl)phenylhydrazone.